Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock!

被引：55

作者：

Marx, GM ^{[1
]}

Steer, CB

Harper, P

Pavlakis, N

Rixe, O

Khayat, D

机构：

[1] Guys Hosp, London SE1 9RT, England

[2] Royal N Shore Hosp, Sydney, NSW, Australia

[3] Salpetriere Hosp, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 06期

关键词：

D O I：

10.1200/JCO.2002.20.6.1446

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1446 / 1448

页数：3

共 22 条

[1]

CROPP G, 2000, P 11 NCI EORTC AACR, pA95

[2] Anti-angiogenic agents: clinical trial design and therapies in development [J].

Deplanque, G ;

Harris, AL .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (13) :1713-1724

[3]

Fong TAT, 1999, CANCER RES, V59, P99

[4]

GORDON M, 2001, EUR J CANC S6, V37, P249

[5]

ICLI F, 1993, CANCER, V72, P587, DOI 10.1002/1097-0142(19930715)72:2<587::AID-CNCR2820720242>3.0.CO

[6]

2-V

[7] Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents [J].

Kakeji, Y ;

Teicher, BA .

INVESTIGATIONAL NEW DRUGS, 1997, 15 (01) :39-48

[8]

Kerbel RS, 2001, J CLIN ONCOL, V19, p45S

[9] Clinical trial designs for cytostatic agents: Are new approaches needed? [J].

Korn, EL ;

Arbuck, SG ;

Pluda, JM ;

Simon, R ;

Kaplan, RS ;

Christian, MC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :265-272

[10] Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors [J].

Kuenen, BC ;

Rosen, L ;

Smit, EF ;

Parson, MRN ;

Levi, M ;

Ruijter, R ;

Huisman, H ;

Kedde, MA ;

Noordhuis, P ;

van der Vijgh, WJF ;

Peters, GJ ;

Cropp, GF ;

Scigalla, P ;

Hoekman, K ;

Pinedo, HM ;

Giaccone, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1657-1667

← 1 2 3 →